Following its positive 2-year results, the MOMENTUM 3 study in patients with heart failure was extended to assess 5-year outcomes of the HeartMate 3™ left ventricular assist device. In this touchCARDIO interview, we speak with Dr Mandeep Mehra (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) to discuss the MOMENTUM 3 study and its findings at both 2 and 5 years.
The abstract entitled ‘5-year Survival with LVAD Therapy in MOMENTUM 3’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- What were the aims, design and eligibility criteria of the MOMENTUM 3 study? (0:21)
- What were the study efficacy and outcomes and how well were they achieved at 2 years? (5:19)
- What have been the 5-year findings, and have any late complications emerged? (7:37)
Disclosures: Mandeep Mehra is a consultant for Abbott, Janssen, Mesoblast, Medtronic, Natera and Paragonix and is on the advisory board for FineHeart, Leviticus, NupulseCV and Transmedics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Devices here and Heart Failure here
Additional Resources: Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. JAMA. 2022; doi: 10.1001/jama.2022.16197.
